Correlations between comutations of HRR-BER or HRR-MMR and tumor mutational burden, neoantigen load, and MSI-H. Correlations between comutations of HRR-BER.

Slides:

Advertisements

Similar presentations

Somatic Mutation Distributions Determining Cut-offs Supp. Figure 5.

Advertisements

Repairing Damages Bases 1. Mismatch repair (MMR) Dam methylase:MutS:

DNA Repair and Cancer. Genome Instability Science, 26 July 2002, p. 544.

Investigating the genetic instability and expression of four DNA repair related proteins in the peripheral lymphocytes of 36 untreated lung cancer patients.

PD-L1 expression patterns in the metastatic tumors to the lung: a comparative study with the primary non-small cell lung cancer Zoran Gatalica1*, Jude.

Development of a Pan-Cancer 15 Gene Expression Signature to Detect a Subgroup Driven by MAPK Signalling Nuala McCabe,1,2 Laura A. Knight, 2 Andrena McCavigan,2.

CCO Independent Conference Highlights

Lung squamous cell carcinoma

From: Epigenetic instability of imprinted genes in human cancers

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Volume 31, Issue 4, Pages e8 (April 2017)

Mismatch Repair Processing of Iododeoxyuridine

Introduction to Checkpoint Inhibitors

The Functional Impact of Alternative Splicing in Cancer

Volume 16, Issue 10, Pages (September 2016)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Molecular Signatures for Tumor Classification

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,

Volume 18, Issue 8, Pages (August 2017)

ML criticality in clinical outcome across cancer types.

Volume 32, Issue 2, Pages e6 (August 2017)

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Hotspot mutations drive clustering of tumor types

Volume 18, Issue 8, Pages (August 2017)

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Volume 165, Issue 1, Pages (March 2016)

Acquired CIN attenuation through APC/C dysfunction in aneuploidy-tolerant p53-null cells. Acquired CIN attenuation through APC/C dysfunction in aneuploidy-tolerant.

Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes Qiancheng Shen, Feixiong Cheng,

The Functional Impact of Alternative Splicing in Cancer

When Genome Maintenance Goes Badly Awry

Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors

The Methylation Landscape of Human Cancers

Distribution of TMB and neoantigen load across tumour types.

Volume 21, Issue 13, Pages (December 2017)

Wynn H. Kao, Adam I. Riker, Deepa S. Kushwaha, Kimberly Ng, Steven A

Figure 1. Relationships among microsatellite instability (MSI; letter A indicates the group with MSI), high tumour ... Figure 1. Relationships among microsatellite.

Peilin Jia, Zhongming Zhao Cell Reports

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Fig. 2 Estimate of the neoantigen repertoire in human cancer.

Combining Immunotherapy and Chemotherapy in NSCLC

Volume 13, Issue 6, Pages (November 2015)

NRG1 rearrangements are found in multiple solid tumors.

Four Key Steps Control Glycolytic Flux in Mammalian Cells

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

CHCHD2 and EGFR protein expression in NSCLC

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

A, Proportion of variants detected in the MMR genes.

Comparison of the frequency of nucleotide variation in the mtDNA D-loop region between stomach and other tumor cell lines. Comparison of the frequency.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Distribution of FGFR aberrancies in urothelial cancers.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Prevalence of germline T790M.

Reduced number and impaired effector functions of TILs in tumors with PTEN deletion or loss-of-function mutations in PTEN. Cutaneous melanoma patients.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Gene expression patterns of SLC and ABC transporters in normal and tumor tissues. Gene expression patterns of SLC and ABC transporters in normal and tumor.

Frequently mutated genes in colorectal cancer.

lncRNA HOXA11-AS is overexpressed in gastric cancer tissues.

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

Validation of NAA's cancer specificity in lung cancer.

Immune profiling of patient-derived organotypic tumor spheroids.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

ERCC2 mutation mapping and distribution across tumor types.

A, heatmap of copy number alterations determined by array CGH for a panel of 79 frozen NSCLC samples. A, heatmap of copy number alterations determined.

Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.

Superenhancers near the KLF5 gene are focally amplified in diverse cancer types. Superenhancers near the KLF5 gene are focally amplified in diverse cancer.

mRNA expression of PARP1 in SCLC cell lines and solid tumors.

TME characteristics of TCGA-STAD subtype and cancer somatic genome.

Comparison of PD-L1 mAbs in IHC across multiple tumor types.

Presentation transcript:

Correlations between comutations of HRR-BER or HRR-MMR and tumor mutational burden, neoantigen load, and MSI-H. Correlations between comutations of HRR-BER or HRR-MMR and tumor mutational burden, neoantigen load, and MSI-H. A, Comparison of TMB or NAL between mutated and wild-type DDR. B–D, ROC curves of the number of comutated DDR pathways to predict higher TMB from TCGA (B) and ICGC (C) databases and higher NAL (D). E, Standard β coefficients between eight DDR pathways and TMB or NAL by multiple linear regression. F, Comparison of TMB/NAL between patients with HRR-BER comutation, HRR-MMR comutation, BER-MMR comutation, and other comutations. G, Frequency of co-mut+ (comutations of HRR-BER or HRR-MMR) in different tumor types. H, Comparison of TMB between the co-mut+ and co-mut− groups in tumors with approved indication of immune therapy. I, Comparison of NAL between the co-mut+ and co-mut− groups in tumors with approved indication for immune therapy. J, The proportions of patients with co-mut+ or MSI-H. K, Comparison of tumor mutational burden in different combinations of comutations and MSI status groups. *, P < 0.05, **, P < 0.01, ***, P < 0.001. CPF, checkpoint factors; FA, Fanconi anemia; NER, nucleotide excision repair; NHEJ, nonhomologous end-joining; TLS, translesion DNA synthesis; BLCA, bladder urothelial carcinoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; NSCLC, non–small-cell lung cancer; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma. Zhijie Wang et al. Cancer Res 2018;78:6486-6496 ©2018 by American Association for Cancer Research